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One of the approaches for the preparation of enantiopure satu-
rated heterocycles is via asymmetric hydrogenation of heteroaro-
matic compounds. Despite considerable progress in this ﬁeld,
hydrogenation of aromatic and heteroaromatic compounds with
high enantioselectivity still remains a great challenge.1
Enantiopure indoline-2-carboxylic acid is an important inter-
mediate for angiotensin I converting enzyme inhibitors (ACE inhib-
itors) which have found application in the treatment of
hypertension such as perindopril,2 pentopril, and indolapril
(Fig. 1).3 The preparation of enantiopure (S)-indoline-2-carboxylic
acid and its methyl ester is generally achieved via classical resolu-
tion,4 chemical synthesis through asymmetric reduction with a
chiral auxiliary5 or via enzymatic methods such as resolution via
hydrolysis of indole-2-carboxylic esters,6a–d or using phenylammo-
nia lyase for the preparation of ortho-chlorophenylalanine fol-
lowed by a copper-catalyzed ring closure.6e Fu et al. have
reported a kinetic resolution of 2-substituted indoles via acylation
using a chiral base as a catalyst.7
In the resolution methods, the yield never exceeds 50%. The
synthesis method through asymmetric reduction using a chiral
auxiliary involves the NaBH4 reduction of prochiral 3-(ortho-ni-
tro-phenyl)pyruvic acid applying the chiral auxiliary D-proline.
The resulting alcohol derivative is then converted into enantioen-
riched (S)-indoline-2-carboxylic acid via four synthetic steps with
an overall yield of 32%, using expensive D-proline.5
In 2000, Ito et al. reported the asymmetric hydrogenation of 2-
substituted N-acetyl and N-Boc-protected indoles with excellent
conversions and enantioselectivities (up to 95% and 78% ee, respec-
tively) using a rhodium catalyst with the trans-chelating bis-phos-ll rights reserved.
aard), b.l.feringa@rug.nl (B.L.phine ligand Ph-TRAP and Cs2CO3 as a base.8 They found that the
base has an important role in obtaining both good catalytic activity
and enantioselectivity. Later, Kuwano et al. reported the Rh-cata-
lyzed asymmetric hydrogenation of N-tosyl-3-substitued indoles9
and the Ru-catalyzed hydrogenation of N-protected-2- and 3-
substituted indoles with excellent enantioselectivities and conver-
sions using the same Ph-TRAP ligand.10
We have developed the use of phosphoramidite ligands in rho-
dium-, ruthenium-, and iridium-catalyzed asymmetric hydrogena-
tion of oleﬁns, ketones, and imines.11 We have also recently
reported the asymmetric hydrogenation of 2,6-substituted quino-
lines12 using an iridium catalyst with the monodentate phospho-
ramidite ligand (S)-PipPhos L1a, with excellent conversions and
ee’s. Phosphoramidites have the advantage of being readily acces-
sible, highly diverse, air stable, and inexpensive compared to most
bidentate ligands.13 In addition, they are amenable to parallel syn-
thesis.14 Herein, we report the asymmetric hydrogenation of 2-
substituted N-protected indoles using rhodium-based catalysts
with monodentate phosphoramidite ligands.
2. Results and discussion
The initial screening of reaction conditions was performed in
dichloromethane at various hydrogen pressures and temperatures
using methyl N-acetylindole-2-carboxylate 1a as a substrate,
5 mol % of [Rh(COD)2]BF4 precursor, and 10 mol % of monodentate
(S)-PipPhos (Table 1). In reactions without additives (entries 1 and
2) no conversion was detected at room temperature and only low
conversion and enantioselectivity were observed at 40 C. As re-
ported by Ito, the addition of a base seems to be crucial in these
hydrogenations.8 Indeed, when 10 mol % of cesium carbonate was
added to the hydrogenation of 1a, full conversion and ee’s up to
74% were obtained (entries 3–7). Further experiments established
that 40 C is optimal, pressure has no inﬂuence and other bases
gave much poorer results. The addition of tri-o-tolylphosphine as
Table 1

















Entry Additive Temp (C) Conv.b (%) eec (%)
1 — 25 0 —
2 — 40 13 12
3 10% Cs2CO3 25 100 73
4d 10% Cs2CO3 25 100 68
5 10% Cs2CO3 40 100 74
6 20% Cs2CO3 40 95 38
7 10% Cs2CO3 60 71 61
8 10% CsF 40 100 72
9 10% KOAc 40 66 60
10 10% Na2CO3 40 2 —
11 10% Li2CO3 40 16 20
12 10% KH2PO4 40 15 10e
13 10% Et3N 40 100 55
14f 10% Cs2CO3 25 65 49
a Reaction conditions: 0.2 mmol of 1a, 0.01 mmol of [Rh(COD)2]BF4, 0.02 mmol of
(S)-PipPhos, 0.02 mmol of Cs2CO3, 25 bar of H2, and 4 mL of CH2Cl2.
b Conversion was determined by 1H NMR.
c Enantioselectivity was determined by GC.
d 100 bar H2
e The opposite conﬁguration of the product was obtained.
f Extra added PPh3 (Rh/PipPhos/PPh3 = 1:2:1)
Table 2










Solvent, 40 oC, 25 bar H2
1a 1b
Entry Solvent Conv.b (%) eec (%)
1 CH2Cl2 100 74
2 EtOAc 59 27
3 i-PrOH 95 8
4 MeOH 0 —
5 THF 16 4
6 Toluene 62 5
a Reaction conditions: 0.2 mmol of 1a, 0.01 mmol of [Rh(COD)2]BF4, 0.02 mmol of
(S)-PipPhos, 0.02 mmol of Cs2CO3, 4 mL of solvent, 40 C, and 25 bar of H2.
b Conversion was determined by 1H NMR.




























Figure 1. (S)-Indoline-2-carboxylic acid and the ACE inhibitors indolapril, pentopril and perindopril.
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not lead to further improvement (65% conversion, 49% ee, entry
14).
We also examined the inﬂuence of the solvent on the reaction
outcome using cesium carbonate as an additive (Table 2). The best
result was obtained in dichloromethane (entry 1). The use of other
solvents led to much reduced rate and enantioselectivities.
Various phosphoramidite ligands L1a–i, L2 were tested under
the optimal reaction conditions in the asymmetric hydrogenation
of 1a (Table 3). The best result was still obtained with (S)-PipPhos
L1a (entry 1). Excellent conversion and an ee of 59% were achievedwith the ligand derived from azepane (L1e, entry 5), while pyrrol-
idine-derived ligand L1d induced a very low ee (Entry 4). With
MonoPhos L1b, 77% conversion and 33% ee were obtained, whereas
the use of ligand L1c surprisingly gave no conversion (entries 2 and
3).
Some other indole derivatives were also screened using (S)-Pip-
Phos at 25 bar of hydrogen pressure (Table 4). The hydrogenation
of unprotected ester 2a to indoline 2b did not proceed, at room
temperature or 40 C, with or without the addition of a base (entry
1, other conditions not shown). This seems to imply that the pro-
tective group on the nitrogen is required in order to achieve coor-
dination of the substrate to the metal. Boc-protected substrate 3a
was hydrogenated with 48% conversion, surprisingly only 4% ee
was found (entry 2). Hydrogenation of acid 4a, was achieved with
low ee, (entries 3 – 6). The best result was obtained in dichloro-
methane, with the addition of cesium carbonate (54% conversion,
37% ee, entry 4).
3. Mechanistic considerations
No mechanistic proposals have been published for the base
dependent rhodium-catalyzed asymmetric hydrogenation of in-
doles. In view of the fact that a catalytic amount of base sufﬁces,
the assumption seems justiﬁed that the base is part of the catalytic
cycle. This is a well-known phenomenon in ruthenium-catalyzed
hydrogenations, where the base serves to create a ruthenium
monohydride species, which is the actual catalyst.17 Thus, we pro-
Table 3




















10 mol% Cs2CO3, CH2Cl2
40 oC, 25 bar H2
1a 1b
Entry Ligand Conv.b (%) eec (%)
1 (S)-L1a R1, R2 = –(CH2)5–, R3 = H 100 74
2 (S)-L1b R1, R2 = Me, R3 = H 77 33
3 (S)-L1c R1, R2 = i-Pr, R3 = H 0 —
4 (S)-L1d R1, R2 = –(CH2)4–, R3 = H 64 2
5 (S)-L1e R1, R2 = –(CH2)6–, R3 = H 93 59
6 (S)-L1f R1, R2 = o-CH2C6H4CH2CH2–R3 = H 87 10
7 (R)-L1g R1, R2 = (S)-PhCH(CH)3, R3 = H 9 26d
8 (S)-L1h R1, R2 = (S)-PhCH(CH)3, R3 = H 0 —
9 (R)-L1i R1, R2 = –(CH2)5–, R3 = Me 60 24e
10 (R)-L2 64 31e
a Reaction conditions: see Table 1 with the exception of T = 40 C.
b Conversion was determined by 1H NMR.
c Enantioselectivity was determined by GC.
d Absolute conﬁguration was determined by comparison of the sign of the spe-
ciﬁc rotation with literature data.
e Opposite conﬁguration of the product observed.
Table 4












2a, R1 = H, R2 = COOMe
3a, R1 = Boc, R2 = COOMe
4a, R1 = Acetyl, R2 = COOH
R1
Entry Indoline Solvent Cs2CO3 T (C) Conv.b (%) eec (%)
1 2b CH2Cl2 + 25 0 —
2 3b CH2Cl2 + 40 48 4
3 4b CH2Cl2 – 40 5 22
4 4b CH2Cl2 + 40 54 37
5 4b Toluene + 40 50 23
6 4b HOAc  40 4 13
a Reaction conditions: 0.2 mmol of substrate, 0.01 mmol of [Rh(COD)2]BF4,
0.02 mmol of PipPhos, 0.02 mmol of Cs2CO3, 4 mL of solvent, 40 C, and 25 bar of H2
b Conversions were determined by 1H NMR.
c Enantioselectivities were determined by HPLC.
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of the cationic bisligated rhodium COD-complex A, the reaction
with hydrogen furnishes dihydrogen complex B, which upon reac-
tion with base forms the neutral rhodiummonohydride complex C.
The reaction with the substrate gives complex D. Insertion of the
indole oleﬁn into the rhodium hydride bond leads to the formation
of rhodiumalkyl complex E, which reacts with dihydrogen to yield
the product and reform hydride C. Trzeciak and co-workers have
shown that isolated rhodium monohydride complexes are good
catalysts for the hydrogenation of aromatic compounds.18 To date,
we have not been able to observe any intermediates using ES-MS.4. Conclusion
In conclusion, full conversion and up to 74% ee have been ob-
tained in the asymmetric hydrogenation of methyl N-acetyl-in-
dole-2-carboxylate 1a using 5 mol % of rhodium catalyst with
10 mol % of monodentate phosphoramidite ligand PipPhos and
10 mol % of cesium carbonate. A protecting group on the nitrogen
was shown to be crucial for obtaining conversion. The presence
of cesium salts has been shown to be necessary to obtain a high
ee. The Boc-protected indole ester 3a was hydrogenated with
48% conversion and only 4% ee, while N-acetyl-indole-2-carboxylic
acid 4a was hydrogenated with up to 54% conversion and 37% ee.
5. Experimental section
5.1. General remarks
The catalysts were prepared in situ. Hydrogenation reactions
were performed in a stainless steal autoclave containing seven
glass vessels (8 mL volume). Magnetic stir bars were placed inside
each vessel, the vessels were closed with septum caps, and the sep-
ta were pierced with syringe needles in order to enable the en-
trance of hydrogen. The autoclave was ﬁlled under air and then
ﬂushed with nitrogen before hydrogen pressure was applied.
NMR spectra were obtained on Varian AMX400 and VXR500 spec-
trometers. Chemical shifts are given in parts per million (ppm) rel-
ative to the residual solvent peak. GC analysis was carried out on
an HP6890 using a ﬂame ionization detector, while HPLC analysis
was performed on a Shimadzu LC-10ADVP HPLC equipped with a
Shimadzu SPD-M10AVP diode array detector. The enantiomeric ex-
cess was determined by HPLC with chiral columns (Chiralcel OD
and OD-H) or by GC with Chiralsil DEX CB, in comparison with
racemic products. Optical rotations were measured on a Schmidt
and Haensch polarimeter (Polartronic MH8) with a 10 cm cell (c gi-
ven in g/100 mL).
Ligands L1a,19 L1b,19 L1c,19 L1d,20 L1e,20 L1f,20 L1g,19 L1h,19
Lli,21 and L221 were prepared according to the literature proce-
dures. Substrates 1a, 2a, and 3awere prepared according to the lit-
erature.8 Substrate 4a was obtained as a gift from DSM
Pharmaceutical Chemicals, Venlo, The Netherlands. Products 1b
and 3b are known compounds.8
5.2. General procedure for hydrogenation
A mixture of [Rh(COD)2]BF4 (4.06 mg, 0.01 mmol), (S)-PipPhos
(7.99 mg, 0.02 mmol), substrate (0.2 mmol), and a base
(0.02 mmol) were dissolved in 4 mL of solvent, in a glass vial
equipped with a stirrer bar. The vial was placed in a stainless steel
autoclave. After the reaction, hydrogen pressure was carefully re-
leased. The solvent was removed in vacuo and conversion was
determined by 1H NMR. The product was puriﬁed on silica.
5.3. 1-Acetyl-2,3-indoline-2-carboxylic acid 4b
This compound exists as mixture of two conﬁgurations due to
the hindered rotation of the acetyl moiety. Both conﬁgurations
are observed at rt by 1H and 13C NMR. At 60 C, only one conﬁgu-
ration was observed (broad signals). White solid; 1H NMR
(500 MHz, (CD3)2NCOD, 60 C) 2.38 (s, 3H), 3.46–3.48 (br, 1H),
3.82–3.84 (br, 1H), 5.37 (d, J = 8.63 Hz, 1H), 7.20 (t, J = 7.35 Hz,
1H), 7.38–7.44 (m, 2H), 8.36 (br, 1H), 13.3 (br, 1H) ppm; 13C
NMR (125 MHz, (CD3)2NCOD, 60 C) 23.3, 33.5, 61.5, 116.6, 123.5,
124.8, 127.5, 129.9, 143.6, 169.2, 173.4 ppm; HPLC (OD, elu-
ent:heptane/i-PrOH/HCOOH = 80/20/1, detector: 254 nm, ﬂow
rate: 1 mL/min), t1 = 9.7 min, t2 = 11.2 min.




































Scheme 1. Proposed hydrogenation mechanism.
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